Fibrinogen and the Coagulation Cascade Study Notes

Fibrinogen is the essential soluble protein in plasma responsible for forming the structural mesh of a blood clot.
The primary goal of the coagulation process is to convert soluble fibrinogen into insoluble fibrin.
Insoluble fibrin forms an electron-microscopic mesh that traps red blood cells and leukocytes, providing the structural integrity of the hemostatic plug.
The hemostatic plug is critical for stabilizing vessel injury and is composed of:
- Platelets.
- Leukocytes.
- Red blood cells.
- A fibrin mesh that seals the components together, contracts, and stabilizes the elements.
This process effectively seals off the area of vascular damage and prevents bleeding.
Fibrinogen is an abundant plasma protein and serves as an acute phase reactant, meaning its concentration can rise significantly (up to tenfold) in response to injury and inflammation.
It is the second most abundant protein in plasma, with its concentration (measured in grams) being surpassed only by albumin.

Fibrinogen has a complex molecular structure consisting of six subunits configured as three paired chains:
- $\alpha$ chains.
- $\beta$ chains.
- $\gamma$ chains.
The molecule contains specific structural and functional regions:
- Coiled-coil domains that connect the various regions.
- The E domain, located at the central part of the molecule.
- The D domain, which is a critical functional domain used in laboratory parameters.
- Fibrinopeptides A and B, located at the top end of the protein, which must be removed to allow for subunit assembly.

Thrombin, a potent enzyme and the central mediator of coagulation, initiates the transition from fibrinogen to fibrin.
Thrombin cleaves fibrinopeptides A and B from the fibrinogen monomer.
Once these peptides are cleaved, "knobs" are exposed on the surface of the resulting fibrin monomer.
These knobs interact with specific "holes" located in the D domains of adjacent fibrin molecules.
Through this interaction, fibrin monomers assemble into polymers, creating long strands.
These strands are subsequently cross-linked by Factor $XIII$ to form a stable, durable fibrin mesh.
The central focus of the entire coagulation cascade is the efficient generation of thrombin to drive this monomer-to-polymer conversion.

Thrombin is generated through the action of upstream serine proteases known as clotting factors.
Most clotting factors are serine proteases, which circulate in the blood as inactive forms called zymogens to prevent spontaneous, dangerous vessel occlusion.
Activation typically involves the cleavage of an "activation peptide" to reveal the catalytic domain.
Specific Clotting Factors and Roles:
- Factor $X$ : A typical serine protease that, once activated (Factor $Xa$ ), is essential for thrombin generation.
- Factor $VIII$ and Factor $V$ : Large, complex proteins that act as cofactors rather than proteases. They enable proteases to assemble and activate on cell surfaces.
Factors are activated sequentially; for example, Factor $X$ is typically activated by Factor $IXa$ and Factor $VIIa$ . Certain snake venoms can also cleave the activation peptide to activate Factor $X$ .
Control mechanisms include SERPENS (serine protease inhibitors) such as antithrombin and $\alpha$ -2 macroglobulin, which turn off these enzymes rapidly to localize the clot.

Clotting factors possess a C-terminal tail containing GLA domains (gamma-carboxyglutamate).
In these domains, glutamic acid (which has a single carboxyl group and one negative charge) is converted into a double carboxyl group (two negative charges).
This conversion is facilitated by Vitamin K and the enzyme gamma-carboxylase.
The increased negative charge allows the GLA domains to interact with negatively charged phospholipid surfaces on activated membranes.
Since both the factor and the membrane are negatively charged, an intermediary "sandwich" of positive ions is required.
Calcium ( $Ca^{2+}$ ) serves as this critical positive bridge, enabling the factors to assemble on the phospholipid surface.
Laboratory Application: Calcium chelators like EDTA are used in blood sample tubes to remove calcium, thereby preventing the blood from clotting by disrupting this assembly.

Free thrombin cannot circulate freely in the blood and must be tightly regulated.
Thrombin ( $IIa$ ) is generated from its precursor, prothrombin ( $II$ ).
The Prothrombinase Complex is the specific assembly responsible for this conversion. It consists of:
- Factor $Xa$ (the protease).
- Factor $Va$ (the cofactor).
- An activated phospholipid membrane surface.
- Calcium ions.
The combination of $10 + 5$ (Factors $Xa$ and $Va$ ) converts Factor $II$ into Factor $IIa$ .

There are two primary arms or pathways that feed into the activation of Factor $X$ :
- Extrinsic Pathway: Driven by Tissue Factor (TF), a surface component typically hidden from the circulation. It is found in high concentrations in atherosclerotic plaques and is released during injury. TF binds to Factor $VII$ to potently activate Factor $X$ .
- Alternate (Intrinsic) Pathway: Involves a sequence of factors starting with Factor $XII$ , which activates Factor $XI$ , which in turn activates Factor $IX$ . Factor $IXa$ works with its cofactor, Factor $VIII$ , to activate Factor $X$ .
The Cascade Model was proposed in the 1960s by McFarlane, Davy, and Ratnoff.
The model explains several key features of coagulation:
- Zymogen Circulation: Proteins circulate inactively to prevent widespread thrombosis and organ damage.
- Amplification: Sequential activation allows for an explosive increase in the amount of active components. For example, $1$ molecule of $XIIa$ can lead to $10$ molecules of $XIa$ , $100$ molecules of $IXa$ , and $1,000$ molecules of $Xa$ .
- Regulation: Multiple steps provide various points where regulators can intervene to turn the process off.
- Surface Efficiency: The process is most efficient when factors assemble on a phospholipid surface.

To prevent the thrombus from getting out of hand and to ensure blood vessels remain patent, the body uses a parallel system driven by the enzyme plasmin.
While thrombin forms fibrin, plasmin breaks down fibrin.
Fibrinolysis is triggered by parallel activators simultaneously with the clotting process.
Digestion of fibrin by plasmin results in various components, most notably the D-dimer.
D-dimer: This specific fragment is only produced when fibrin has been formed and cross-linked, as it comprises a D domain from two adjacent fibrin molecules. Its presence in the blood is a laboratory marker indicating that fibrin has been formed.
Regulation of Fibrinolysis:
- Plasmin Inhibitors (e.g., $PI1$ ): These turn off clot lysis to maintain stability when necessary.
- Plasminogen Activators: These include TPA (tissue plasminogen activator) and neurokinase, which trigger plasmin formation and are used therapeutically to unblock vessels.